Fluorodeoxyglucose

Fluorodeoxyglucose
Name	Fluorodeoxyglucose
Drug class	Radiopharmaceutical
Molecular formula	C6H11[^18F]O5

Florodeoxyglucose is a radiolabeled glucose analogue widely used as a positron-emitting radiopharmaceutical in molecular imaging. It serves as a metabolic tracer in clinical computed tomography-guided and standalone positron emission tomography studies across oncology, neurology, and cardiology, and it is produced and regulated within frameworks involving institutions such as International Atomic Energy Agency, Food and Drug Administration, and national nuclear medicine centers. Developed from foundational research in glucose metabolism and radiochemistry by groups connected to institutions like Brookhaven National Laboratory, Argonne National Laboratory, Memorial Sloan Kettering Cancer Center, and universities including Johns Hopkins University and Harvard University, it underpins contemporary molecular imaging workflows at centers such as Mayo Clinic, Cleveland Clinic, and Massachusetts General Hospital.

Chemistry and Radiopharmaceutical Properties

Fluorodeoxyglucose is a 2-deoxy-2-[^18F]fluoro-D-glucose analogue of D-glucose with substitution at the C-2 position producing altered biochemical behavior relative to native glucose; its radionuclide, fluorine-18, is a positron emitter produced in cyclotrons at facilities like TRIUMF and Oak Ridge National Laboratory. The molecule's physicochemical properties—hydrophilicity, stereochemistry derived from Fischer projection conventions, and a positron range determined by fluorine-18 decay—affect imaging resolution in scanners from manufacturers such as Siemens Healthineers, GE Healthcare, and Philips. Quality attributes evaluated under pharmacopeial standards by organizations such as United States Pharmacopeia, European Medicines Agency, and International Atomic Energy Agency include radiochemical purity, specific activity, pH, residual solvents, and sterility, all critical for compliance with directives and guidances from bodies including European Commission and Food and Drug Administration.

Synthesis and Production

Production commonly uses nucleophilic substitution of a protected mannose triflate precursor with [^18F]fluoride generated by proton irradiation of ^18O-water in hospital or regional cyclotrons operated by enterprises like IBA (company) and Advanced Cyclotron Systems. Automated synthesis modules from vendors such as GE Healthcare and Siemens Healthineers perform nucleophilic fluorination, hydrolysis, and purification under Good Manufacturing Practice frameworks enforced by agencies like Medicines and Healthcare products Regulatory Agency and Health Canada. Distribution logistics involve cold kits, shielded transport cassettes managed under regulations from International Air Transport Association and national postal authorities, as practiced by networks including PETNet Solutions and academic radiopharmacies at University of California, San Francisco and Stanford University.

Mechanism of Action and Pharmacokinetics

After intravenous administration, FDG is transported into cells by facilitative glucose transporters characterized in studies associated with Albert Szent-Györgyi-related metabolism research and modern cell biology groups at Max Planck Society-affiliated institutes; transporters such as those identified by Ernest Beutler-era biochemistry are analogously implicated. Intracellular phosphorylation by hexokinase yields FDG-6-phosphate, which is metabolically trapped because it is not a substrate for phosphoglucose isomerase; kinetic models used in quantification were developed alongside work at Stanford University and Massachusetts Institute of Technology and utilize compartmental analysis popularized by investigators from University of California, San Diego and Columbia University. Clearance and biodistribution reflect renal excretion patterns managed clinically at centers like Johns Hopkins Hospital and are influenced by physiologic states studied by groups at National Institutes of Health, with half-life dictated by fluorine-18 decay (approximately 110 minutes) impacting scheduling and workflow in facilities such as Memorial Sloan Kettering Cancer Center.

Clinical Applications

FDG PET imaging is central to staging, restaging, and response assessment in malignancies managed at oncology centers such as Dana-Farber Cancer Institute, MD Anderson Cancer Center, and Royal Marsden Hospital; common indications include lymphoma, non-small cell lung cancer, colorectal cancer, and melanoma evaluated per guidelines from American Society of Clinical Oncology and National Comprehensive Cancer Network. Neurology applications at institutions like Mayo Clinic and University College London Hospitals include evaluation of epilepsy, dementia syndromes, and brain tumor metabolism, with protocols influenced by consensus from bodies such as European Association of Nuclear Medicine and American College of Radiology. In cardiology programs at Cleveland Clinic and Mount Sinai Health System, FDG PET assesses myocardial viability and inflammatory cardiomyopathies guided by position statements from American Heart Association.

Imaging Techniques and Interpretation

Acquisition protocols vary across hybrid systems combining PET with computed tomography or magnetic resonance imaging from suppliers like Siemens Healthineers and GE Healthcare; standardized uptake value (SUV) metrics and visual grading scales are interpreted by multidisciplinary teams at comprehensive cancer centers including Royal Marsden Hospital and Vall d'Hebron University Hospital. Image reconstruction, attenuation correction, and partial-volume effects are technical considerations addressed in research from Lawrence Berkeley National Laboratory and academic groups at University of Pennsylvania and Yale University. Reporting frameworks such as PERCIST and Deauville criteria have been promulgated by panels convened by European Organization for Research and Treatment of Cancer and International Atomic Energy Agency collaborators to harmonize interpretation across networks like European Association of Nuclear Medicine and National Cancer Institute cooperative groups.

Safety, Dosimetry, and Adverse Effects

Radiation dosimetry models for FDG incorporate biokinetic data contributed by investigators at International Commission on Radiological Protection and National Council on Radiation Protection and Measurements; typical effective doses are benchmarked against diagnostic standards used by World Health Organization and regional regulators. Safety procedures practiced in nuclear medicine departments at Brigham and Women's Hospital and Toronto General Hospital include radiation protection principles from International Atomic Energy Agency and occupational guidance by International Labour Organization. Adverse effects are rare and include hypersensitivity reactions documented in pharmacovigilance databases maintained by Food and Drug Administration and European Medicines Agency, while renal impairment and glycemic status—monitored following protocols from American Diabetes Association—influence preparation and interpretation.

Regulatory and Quality Control Considerations

Regulatory oversight encompasses marketing authorization, batch release, and Good Manufacturing Practice inspections by agencies such as Food and Drug Administration, European Medicines Agency, and national competent authorities in systems like National Health Service; pharmacopeial monographs from United States Pharmacopeia and European Pharmacopoeia specify tests for radiochemical purity and sterility. Quality control laboratories in academic and commercial radiopharmacies at institutions such as Vanderbilt University Medical Center and companies including Curium (company) implement validated assays, environmental monitoring, and release criteria consistent with guidances from International Atomic Energy Agency and harmonization efforts by International Organization for Standardization. Continuous professional education and credentialing for practitioners are maintained through bodies like Society of Nuclear Medicine and Molecular Imaging and European Association of Nuclear Medicine.

Category:Radiopharmaceuticals